Nilotinib Zentiva (Nilotinib)

Nilotinib selectively binds to the ATP‑binding site of the BCR‑ABL fusion protein, blocking its kinase activity. This inhibition stops downstream signaling pathways that promote cell proliferation and survival, leading to apoptosis of the leukemic cells while sparing most normal cells.

The dose of Nilotinib Zentiva is determined by the prescribing physician based on the patient’s clinical condition, disease phase, and tolerance. Dosing regimens are individualized and should follow the prescriber’s written instructions.

Nilotinib is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and effective contraception is required. Breastfeeding is not recommended while on therapy because the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nilotinib belongs to the second‑generation tyrosine kinase inhibitor class, offering higher potency against BCR‑ABL than first‑generation agents such as imatinib. It provides faster and deeper molecular responses in many patients, though safety profiles differ and individual tolerability must be considered.

Store Nilotinib Zentiva at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture, heat, and direct sunlight to maintain product stability.

Nilotinib Zentiva is taken orally, usually with a low‑fat meal to improve absorption. The tablets should be swallowed whole with water and not crushed or chewed. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include QT interval prolongation, which can lead to serious cardiac arrhythmias, and severe hepatic or pancreatic toxicity. Regular monitoring of ECG, liver function tests, and pancreatic enzymes is recommended to detect these adverse events early.

Nilotinib should not be used by patients with a known hypersensitivity to the drug or any of its excipients, those with a history of significant QT prolongation, uncontrolled cardiac disease, or severe hepatic impairment. Pregnant women and breastfeeding mothers must also avoid this medication.